This remarkable finding acted as a catalyst for the development of the current ALENO trial, which aims to investigate the activity and efficacy of alectinib as NAT in surgically resectable stage III ALK+ NSCLC [52]. Here, BRD2 is linked to non-small cell lung carcinoma.